Healthcare Contract Development And Manufacturing Organization

Healthcare Contract Development And Manufacturing Organization Market Outlook

The global Healthcare Contract Development and Manufacturing Organization (CDMO) market is expected to reach approximately USD 180 billion by 2035, growing at a compound annual growth rate (CAGR) of roughly 8% during the forecast period from 2025 to 2035. This growth is driven by the increasing demand for pharmaceutical outsourcing, innovation in biopharmaceuticals, and the rising trend towards personalized medicine, which necessitates more flexible and adaptive manufacturing solutions. Furthermore, the COVID-19 pandemic has accelerated the need for robust and scalable manufacturing capabilities, pushing pharmaceutical companies to seek strategic partnerships with CDMOs to enhance their production processes. The focus on regulatory compliance, quality assurance, and the necessity for rapid turnaround times in drug production have further solidified the importance of CDMOs in the healthcare ecosystem. As the industry evolves, the integration of advanced technologies such as artificial intelligence and automation in manufacturing processes will also likely propel market growth.

Growth Factor of the Market

The healthcare CDMO market is primarily driven by the rising trend of outsourcing among pharmaceutical and biotechnology companies, which allows them to focus on core competencies while leveraging outsourced expertise for manufacturing and development. Additionally, the demand for biologics and complex molecules, which require specialized manufacturing techniques, has led to an increased reliance on CDMOs that possess the necessary capabilities and technologies. The expansion of the global pharmaceutical market, particularly in emerging economies, is contributing to the growth of CDMOs as companies seek to enter new markets and meet local production regulations efficiently. Furthermore, the advancements in drug development processes and the increasing complexity of drug formulations necessitate specialized services that CDMOs can provide, thus fueling the market. The increasing prevalence of chronic diseases and the subsequent rise in demand for innovative therapies further emphasize the need for efficient contract manufacturing solutions.

Key Highlights of the Market

• Expansion of outsourcing trends among pharmaceutical and biotech companies.
• Increasing demand for biologics and complex drug formulations.
• Advancements in technology facilitating more efficient production processes.
• Growing prevalence of chronic diseases driving the need for innovative treatments.
• Strategic partnerships between manufacturers and CDMOs enhancing operational efficiency.

By Service Type

Contract Manufacturing:

Contract manufacturing serves as a critical component of the healthcare CDMO market, where companies leverage external firms to produce their drug products. This service type is particularly appealing to pharmaceutical companies looking to minimize production costs, optimize their supply chain, and enhance flexibility in manufacturing capacities. With the increasing complexity of drug formulations and the demand for customized manufacturing processes, contract manufacturing enables firms to focus on research and development while ensuring that high-quality products are produced in compliance with regulatory standards. Moreover, the growing trend of personalized medicine is driving demand for contract manufacturing services, as companies seek more tailored solutions to meet specific patient needs.

Contract Development:

Contract development services in the healthcare CDMO market encompass a range of activities, including formulation development, method development, and stability studies. These services are essential for pharmaceutical companies in the early stages of drug development, allowing them to validate their formulations and ensure efficacy and safety before moving to large-scale manufacturing. By outsourcing these development processes, companies can benefit from the expertise and experience of CDMOs, which often have specialized teams and advanced technologies at their disposal. This not only accelerates the time to market for new drugs but also enhances the overall quality of the developed products, making contract development a crucial aspect of the healthcare CDMO landscape.

API Manufacturing:

Active Pharmaceutical Ingredient (API) manufacturing is a key segment within the healthcare CDMO market, focusing on the production of the primary ingredients used in drug formulations. The API manufacturing process requires stringent adherence to regulatory standards and quality control measures, making it vital for CDMOs to possess robust capabilities in this area. The increasing complexity of drug formulations and the rise in demand for generic and biosimilar products have led to a surge in API manufacturing activities. As pharmaceutical companies strive to optimize costs while ensuring high-quality production, outsourcing API manufacturing to specialized CDMOs has become a strategic move to enhance operational efficiency and maintain compliance with global regulatory requirements.

Formulation Development:

Formulation development is a critical service offered by healthcare CDMOs, encompassing the creation of effective and stable formulations for various drug delivery systems. This segment of the market is witnessing growing demand as pharmaceutical companies are increasingly focusing on tailored formulations that cater to specific patient populations and disease states. CDMOs play a vital role in this process by leveraging their expertise in formulation science, which includes selecting appropriate excipients, optimizing dosage forms, and conducting stability testing. The complexity of modern therapeutics, including biologics and combination therapies, necessitates specialized formulation development services, positioning CDMOs as indispensable partners in bringing innovative products to market.

Packaging:

Packaging services in the healthcare CDMO market are essential for ensuring the integrity, safety, and compliance of pharmaceutical products throughout their lifecycle. This service type includes primary packaging, secondary packaging, and labeling, all of which must adhere to stringent regulatory standards. As companies increasingly recognize the importance of packaging in protecting drug products and enhancing patient compliance, the demand for sophisticated packaging solutions has grown. CDMOs that offer packaging services are well-positioned to provide end-to-end solutions that streamline the manufacturing process while ensuring that products are properly labeled and packaged for distribution. The integration of technology in packaging processes, such as serialization and anti-counterfeiting measures, further underscores the significance of this service in the healthcare CDMO landscape.

By User

Pharmaceutical Companies:

Pharmaceutical companies represent a significant segment of the healthcare CDMO market, as they frequently rely on contract development and manufacturing organizations to enhance their operational capabilities. These companies often face increasing pressure to bring new drugs to market quickly while controlling costs, making partnerships with CDMOs a strategic choice. By outsourcing manufacturing processes, pharmaceutical firms can capitalize on the specialized expertise and resources that CDMOs offer, allowing them to focus on their core functions of research and development, marketing, and regulatory compliance. This collaboration not only streamlines the manufacturing process but also ensures adherence to stringent quality standards necessary for pharmaceutical products.

Biotechnology Companies:

Biotechnology companies are another key user segment within the healthcare CDMO market, leveraging contract development and manufacturing services to produce biologic therapeutics and novel drugs. The intricate nature of biologics, which often involve complex production processes and stringent regulatory requirements, makes outsourcing to specialized CDMOs a practical solution for biotech firms. By collaborating with CDMOs, biotechnology companies can access advanced manufacturing technologies, analytical capabilities, and expertise in navigating the regulatory landscape, thereby accelerating the development and commercialization of their innovative drugs. Additionally, this partnership allows biotech firms to allocate resources more efficiently by focusing on research and product development while relying on CDMOs for large-scale production.

Medical Device Companies:

Medical device companies are increasingly turning to contract development and manufacturing organizations as they seek to streamline their production processes and enhance product quality. CDMOs can provide specialized expertise in the development and manufacturing of complex medical devices, ensuring compliance with stringent industry regulations and standards. By outsourcing, medical device companies can benefit from reduced production costs, improved time-to-market for new devices, and enhanced flexibility in their manufacturing capabilities. CDMOs also offer valuable insights into regulatory matters, quality assurance, and supply chain management, which are crucial for ensuring that medical devices meet the required safety and efficacy standards.

Research Institutes:

Research institutes play a vital role in the healthcare CDMO market as they often collaborate with CDMOs to facilitate drug development and testing processes. These organizations typically require specialized services for the development of new drug candidates, including formulation development, stability testing, and clinical trial support. By partnering with CDMOs, research institutes can leverage access to advanced technologies, robust infrastructure, and regulatory expertise that may not be available in-house. Furthermore, this collaboration allows research institutes to focus on their core mission of advancing scientific knowledge and innovation while outsourcing the operational aspects of drug development to experienced CDMOs.

Others:

The 'Others' category in the user segment encompasses various organizations that utilize healthcare CDMO services, including government agencies, non-profit organizations, and academic institutions. These entities may require contract development and manufacturing services for various projects, including vaccine production, public health initiatives, and research collaborations. As the demand for specialized manufacturing capabilities grows, these organizations are increasingly recognizing the benefits of partnering with CDMOs to achieve their objectives efficiently. CDMOs provide the necessary infrastructure, expertise, and regulatory knowledge to support diverse projects, making them valuable allies for a wide range of users in the healthcare ecosystem.

By Therapeutic Area

Oncology:

Oncology is one of the fastest-growing therapeutic areas within the healthcare CDMO market, driven by the increasing incidence of cancer and the ongoing research into innovative therapies. CDMOs play a crucial role in the development and manufacturing of oncology drugs, including chemotherapeutics, targeted therapies, and immunotherapies. The complexity of oncology drug formulations requires specialized expertise, making CDMOs essential partners for pharmaceutical companies focused on this therapeutic area. Furthermore, the growing trend towards personalized medicine in oncology has increased the demand for tailored formulations, which CDMOs are well-equipped to provide through their advanced capabilities and regulatory knowledge.

Infectious Diseases:

The therapeutic area of infectious diseases is witnessing significant growth, particularly in light of recent global health crises such as the COVID-19 pandemic. Healthcare CDMOs are vital in developing and manufacturing vaccines, antiviral drugs, and other treatments aimed at combating infectious agents. The need for rapid vaccine development and distribution has underscored the importance of CDMOs in the healthcare ecosystem, as they possess the flexibility and expertise to scale production quickly in response to emerging threats. With the ongoing global focus on infectious diseases, the demand for CDMO services in this area is expected to continue to grow, positioning these organizations as key players in public health initiatives.

Cardiovascular Diseases:

Cardiovascular diseases remain a leading cause of morbidity and mortality worldwide, driving the demand for innovative therapies and interventions. CDMOs are increasingly involved in the development and manufacturing of drugs aimed at treating various cardiovascular conditions, including hypertension, heart failure, and atherosclerosis. The complexity of cardiovascular drug formulations necessitates specialized manufacturing processes, making CDMOs essential for pharmaceutical companies seeking to bring new therapies to market efficiently. As the prevalence of cardiovascular diseases continues to rise, the role of CDMOs in supporting the development of effective treatments will become even more critical.

Central Nervous System Disorders:

The treatment of central nervous system (CNS) disorders, including depression, anxiety, and neurodegenerative diseases, is a rapidly evolving therapeutic area within the healthcare CDMO market. The complexity of CNS drug formulations requires advanced manufacturing techniques and a deep understanding of the underlying science. CDMOs are well-positioned to support pharmaceutical companies in developing innovative CNS therapies, leveraging their expertise in formulation development, regulatory compliance, and quality assurance. The growing focus on mental health and neurodegenerative conditions is likely to drive demand for CDMO services in this area, underscoring their importance in advancing treatment options for patients.

Others:

The 'Others' category in the therapeutic area segment encompasses various conditions and diseases that may not fall under the primary categories mentioned earlier. This includes therapeutic areas such as gastrointestinal disorders, respiratory diseases, and rare diseases. The diversity of conditions within this category highlights the broad applicability of healthcare CDMOs across the pharmaceutical landscape. By offering specialized services that cater to the unique needs of different therapeutic areas, CDMOs can support pharmaceutical companies in their quest for effective treatments. The increasing emphasis on rare disease research and the development of niche therapeutics further amplifies the relevance of CDMOs in this segment.

By Region

The North America region is projected to dominate the healthcare CDMO market, accounting for approximately 45% of the global market share by 2035. This dominance can be attributed to the presence of established pharmaceutical and biotechnology companies within the region, as well as the continuous innovation in drug development and manufacturing processes. The regulatory framework in North America fosters a conducive environment for the growth of CDMOs, allowing for accelerated timelines in bringing new products to market. Furthermore, the increasing prevalence of chronic diseases and the rising focus on personalized medicine are driving the demand for specialized CDMO services in this region. It is anticipated that North America will maintain its leading position, with a CAGR of around 8.5% during the forecast period.

Europe is also expected to be a significant player in the healthcare CDMO market, holding a share of approximately 30% by 2035. The region is characterized by a strong emphasis on research and development, supported by government initiatives aimed at fostering innovation in the pharmaceutical sector. The increasing collaboration between CDMOs and pharmaceutical companies in Europe is further enhancing the operational efficiency and productivity of drug development processes. The rising demand for biologics and complex molecules in Europe is driving the need for specialized contract manufacturing services, enabling CDMOs to capitalize on emerging opportunities. The CAGR for Europe is projected to be around 7.5% during the forecast period, reflecting the ongoing growth in the region's healthcare CDMO landscape.

Opportunities

The healthcare CDMO market presents numerous opportunities, primarily driven by the ongoing advancements in biopharmaceuticals and the increasing complexity of drug formulations. As pharmaceutical and biotechnology companies strive to develop novel therapeutics, they are increasingly seeking the expertise of CDMOs to navigate the challenges associated with advanced manufacturing processes. The growing trend towards personalized medicine further amplifies these opportunities, as CDMOs are well-equipped to provide tailored solutions that meet the specific needs of individual patients. Additionally, the rise of digital technologies and automation in manufacturing processes is creating new avenues for efficiency and cost reduction, allowing CDMOs to enhance their service offerings and attract a broader client base. Furthermore, the expansion of the global pharmaceutical market, particularly in emerging economies, presents lucrative opportunities for CDMOs to establish their presence and support local drug development initiatives.

Another significant opportunity lies in the increasing focus on sustainability and environmentally friendly manufacturing practices within the healthcare sector. As regulatory pressures and consumer demands for sustainable practices continue to rise, CDMOs that prioritize eco-friendly approaches in their operations will be better positioned to differentiate themselves in the market. By adopting green manufacturing processes, optimizing resource utilization, and minimizing waste, CDMOs can not only enhance their operational efficiency but also appeal to environmentally conscious clients. Moreover, strategic partnerships and collaborations with research institutions, pharmaceutical companies, and governmental agencies can further bolster the capabilities of CDMOs, enabling them to tap into new markets and expand their service offerings. Overall, the healthcare CDMO market is ripe with opportunities, and organizations that leverage these trends will be well-positioned for future growth.

Threats

Despite the promising growth prospects, the healthcare CDMO market faces several threats that could hinder its progress. One of the primary concerns is the increasing competition among CDMOs, which can lead to price wars and reduced profit margins. As more players enter the market, especially in emerging economies, established CDMOs may find it challenging to maintain their competitive edge. This saturation can potentially result in a race to the bottom, where quality may be compromised in the pursuit of lower prices. Additionally, regulatory compliance remains a critical issue for CDMOs, as failure to meet stringent quality standards can result in significant legal and financial repercussions. The evolving regulatory landscape necessitates continuous investment in quality assurance and compliance processes, which can place a strain on resources and affect overall profitability.

Furthermore, supply chain disruptions, as witnessed during the COVID-19 pandemic, pose a significant threat to the healthcare CDMO market. The reliance on global supply chains for raw materials and components can lead to vulnerabilities, particularly during times of crisis. Events such as geopolitical tensions, natural disasters, or pandemics can disrupt the flow of materials and impact the ability of CDMOs to meet production timelines. This unpredictability can undermine client trust and satisfaction, ultimately affecting business relationships. As the market continues to evolve, CDMOs must remain vigilant and proactive in addressing these threats while ensuring resilience in their operations to navigate potential challenges effectively.

Competitor Outlook

• Lonza Group
• Catalent, Inc.
• Samsung Biologics
• WuXi AppTec
• Eurofins Scientific
• Fujifilm Diosynth Biotechnologies
• Recipharm AB
• Patheon (Thermo Fisher Scientific Inc.)
• Boehringer Ingelheim
• AMRI (Albany Molecular Research Inc.)
• CMO (Contract Manufacturing Organization)
• Rottendorf Pharma
• KBI Biopharma
• Vetter Pharma International
• Baxter International Inc.

The competitive landscape of the healthcare CDMO market is characterized by a diverse array of players, ranging from large multinational corporations to specialized niche firms. Major players such as Lonza Group and Catalent, Inc. are at the forefront of the market, offering a comprehensive suite of services that encompass contract development and manufacturing across various therapeutic areas. These companies leverage their extensive experience, advanced technologies, and robust regulatory compliance capabilities to attract clients from pharmaceutical and biotechnology sectors. Additionally, strategic acquisitions and partnerships are common strategies employed by these companies to expand their service offerings and geographic reach, enhancing their competitive positioning in the market.

Emerging players like WuXi AppTec and Samsung Biologics are also making significant strides in the healthcare CDMO market, as they capitalize on the growing demand for biopharmaceutical manufacturing services. These companies have invested heavily in state-of-the-art facilities and cutting-edge technologies to deliver high-quality products and services to their clients. By focusing on innovation and customer-centric approaches, these firms are well-positioned to compete with established players and capture a larger share of the market. Furthermore, the increasing emphasis on sustainability and environmentally friendly practices is driving competition among CDMOs, as companies seek to differentiate themselves through eco-conscious initiatives and practices.

Key companies in the healthcare CDMO market, such as Boehringer Ingelheim and Patheon, are known for their extensive service portfolios and specialized expertise in drug development and manufacturing. These organizations have established themselves as trusted partners for pharmaceutical companies, providing end-to-end solutions that streamline the drug development process. Their robust capabilities in areas like biologics, small molecules, and advanced therapies enable them to cater to a wide range of client needs. As the market continues to evolve, these companies are likely to maintain their leadership positions while adapting to emerging trends and challenges in the healthcare landscape.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Lonza Group
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 WuXi AppTec
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Recipharm AB
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 KBI Biopharma
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Catalent, Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Rottendorf Pharma
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Samsung Biologics
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Eurofins Scientific
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Boehringer Ingelheim
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Baxter International Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Vetter Pharma International
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Fujifilm Diosynth Biotechnologies
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 AMRI (Albany Molecular Research Inc.)
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Patheon (Thermo Fisher Scientific Inc.)
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 CMO (Contract Manufacturing Organization)
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Healthcare Contract Development And Manufacturing Organization Market, By User
    • 6.1.1 Pharmaceutical Companies
    • 6.1.2 Biotechnology Companies
    • 6.1.3 Medical Device Companies
    • 6.1.4 Research Institutes
    • 6.1.5 Others
  • 6.2 Healthcare Contract Development And Manufacturing Organization Market, By Service Type
    • 6.2.1 Contract Manufacturing
    • 6.2.2 Contract Development
    • 6.2.3 API Manufacturing
    • 6.2.4 Formulation Development
    • 6.2.5 Packaging
  • 6.3 Healthcare Contract Development And Manufacturing Organization Market, By Therapeutic Area
    • 6.3.1 Oncology
    • 6.3.2 Infectious Diseases
    • 6.3.3 Cardiovascular Diseases
    • 6.3.4 Central Nervous System Disorders
    • 6.3.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Healthcare Contract Development And Manufacturing Organization Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Healthcare Contract Development And Manufacturing Organization market is categorized based on

By Service Type

• Contract Manufacturing
• Contract Development
• API Manufacturing
• Formulation Development
• Packaging

By User

• Pharmaceutical Companies
• Biotechnology Companies
• Medical Device Companies
• Research Institutes
• Others

By Therapeutic Area

• Oncology
• Infectious Diseases
• Cardiovascular Diseases
• Central Nervous System Disorders
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Lonza Group
• Catalent, Inc.
• Samsung Biologics
• WuXi AppTec
• Eurofins Scientific
• Fujifilm Diosynth Biotechnologies
• Recipharm AB
• Patheon (Thermo Fisher Scientific Inc.)
• Boehringer Ingelheim
• AMRI (Albany Molecular Research Inc.)
• CMO (Contract Manufacturing Organization)
• Rottendorf Pharma
• KBI Biopharma
• Vetter Pharma International
• Baxter International Inc.